Fennec Pharmaceuticals Inc. (FENC)

Market Cap	212.53M
Revenue (ttm)	n/a
Net Income (ttm)	-17.38M
Shares Out	26.24M
EPS (ttm)	-0.63
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	184,143
Open	7.96
Previous Close	8.04
Day's Range	7.75 - 8.19
52-Week Range	3.82 - 10.08
Beta	0.09
Analysts	Buy
Price Target	10.81 (+33.5%)
Earnings Date	Nov 8, 2022

About FENC

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

• Industry: Biotechnology
• IPO Date: Jun 5, 2001
• CEO: Rostislav Raykov
• Employees: 10
• Stock Exchange: NASDAQ
• Ticker Symbol: FENC

Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 10 analysts, the average rating for FENC stock is "Buy." The 12-month stock price forecast is 10.81, which is an increase of 33.46% from the latest price.

Price Target

$10.81

(33.46% upside)

Analyst Consensus: Buy

Stock Forecasts